MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Pioneers: Research_Academia, Government Labs, Non-Profits, Industry
*Pioneers: Triple Helix & Regional Innovation Clusters (RICs) -Intermediaries
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
*Industry: Ireland
Pfizer Inc. (NYSE: PFE)
Organization & Developments: Pfizer
Parents
Pfizer Inc. (NYSE: PFE)
Children
*Centers for Therapeutic Innovation, Pfizer
*Comirnaty (COVID-19 vaccine mRNA)
*Continued collaboration with BioNTech on mRNA vaccines for flu and RSV.
*Developments: Pfizer
*Diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products
*Eliquis (apixaban)
*Information Management Requirements for Pharmaceuticals Trials
*Lung Cancer Master Protocol, or Lung-MAP
*Organization: Pfizer
*Pfizer Healthcare Ireland
*Pfizer: Brands
*Pfizer: New Product R&D and Business Developments
*World’s largest drug maker
2022 Pfizer (PFE)\ Investor Presentation - Slideshow_ seekingalpha.com
2022 Pfizer: Q3 Earnings Review - Planning For Life After COVID- seekingalpha.com
2022: CytoReason, Pfizer ink $110M, 5-year extension of AI-powered drug development deal
2022: How Pfizer Won the Pandemic, Reaping Outsize Profit and Influence
2022: Pfizer 'surprised' by Moderna COVID-19 vaccine patent lawsuit
2022: Pfizer Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Pfizer launches health equity initiative for 45 lower-income countries
2022: Pfizer Talks Up Its Pipeline_ seekingalpha.com
2022: Pfizer: COVID-19 May Never End_ seekingalpha.com
2022: Pfizer: Covid-19 Treatment Isn't Only Expansion Opportunity On Deck_seekingalpha.com
2022: Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNA - Keep An Eye On This Space
2022: Racing Moderna, Pfizer starts phase 3 trial of mRNA flu vaccine
2022: Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target_ voyagertherapeutics
2023: Pfizer 2024 Guidance - Relentless COVID Pain Isn't Over_ seekingalpha.com
2023: Pfizer Q1 Earnings: COVID Franchise Outperforms While Investors Play Long Game_ seekingalpha.com
2023: Pfizer Shares Have Priced In The Expected Earnings Declines_ seekingalpha.com
2023: Pfizer Stock: Interesting, If Discipline Returns
2023: Pfizer: Between Hope, Despair, And A 5.7% Yield_ seekingalpha.com
2023: Pfizer: Brutal End To COVID Gravy Train
2023: Pfizer: Buy The Panic_ seekingalpha.com
2023: Pfizer: Buy This Big Pharma Stock For Safe Income And Deep Value (NYSE:PFE)
2023: Pfizer: Protracted Selloff Makes This Best Time To Buy For A Decade
2023: Pfizer: Recent COVID-Related Headlines Call For An Updated Assessment _ seekingalpha.com
2023: Pfizer: Value Investment Opportunity After Recent Price Decline_seekingalpha.com
2023: Pfizer: Washed-Out And On The Verge Of A Huge Turnaround
2023: Pfizer's Sequel: Return Of The Value Stock
2023: The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations_ seekingalpha.com
2024: 2024 Turnaround: Bottom Fishing With Pfizer
2024: 3 Factors That Make Pfizer's Ultra-High-Yield Dividend Safer Than You Might Think
2024: 3 Potential Catalysts That Could Lift Pfizer Stock Before 2025
2024: 6%-Yielding Pfizer Is An Ultra-Deep-Value Gem In An Expensive Market
2024: After Pfizer’s coronavirus vaccine success, CEO targeted for revenue slump
2024: Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysis
2024: Is Pfizer (NYSE:PFE) a High-Yielding Dividend Stock Worth Buying?
2024: Lock In A Phenomenal Yield With Pfizer_seekingalpha.com
2024: Pfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A Talk
2024: Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort_ seekingalpha.com
2024: Pfizer issues global market withdrawal of sickle cell disease therapy Oxbryta
2024: Pfizer Jumps After Activist Investor Starboard Reportedly Takes $1 Billion Stake
2024: Pfizer Quietly Gaining Momentum_seekingalpha.com
2024: Pfizer Stock: A Golden Buying Opportunity (Rating Upgrade)
2024: Pfizer, joining Lilly, enters the direct-to-consumer market with a telehealth and prescription platform
2024: Pfizer: A 6% Yielding Ultra SWAN Bargain With Upside Potential
2024: Pfizer: A 6% Yielding Value Deal
2024: Pfizer: A Strong Buy Trading Below A 10 P/E Ratio
2024: Pfizer: A Strong Product Pipeline Could Lead To Significant Upside
2024: Pfizer: Activists Clouding A Promising Picture
2024: Pfizer: Attractive Valuation And A Strong Pipeline Mitigate Patent Cliff Concerns
2024: Pfizer: Buy The Plunge For Rebound Potential And Get Paid A 6% Yield
2024: Pfizer: Discounted For A Reason - But Dividend Story Remains Rich
2024: Pfizer: Growing Beyond Covid
2024: Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks
2024: Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks
2024: Pfizer: I'm Short-Term Skeptical, Long-Term Positive Post 2025 Guidance Call
2024: Pfizer: Irrational Anti-Vaccine Fear_ seekingalpha.com
2024: Pfizer: It's Darkest Before The Dawn, Upgrading To 'Strong Buy'_seekingalpha.com
2024: Pfizer: One Of The Next Big AI Winners
2024: Pfizer: Paying Too Much To Boost Revenues_ seekingalpha.com
2024: Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns
2024: Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns_ seekingalpha.com
2024: Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disagree With The Market
2024: Pfizer: Simply Too Cheap To Ignore
2024: Pfizer: The Market Is Wrong
2024: Pfizer: The Rally May Just Be Getting Started
2024: Pfizer: Tracking Well Above The Industry
2024: Pfizer: Turnaround Is Gaining Momentum
2024: Pfizer: Turning The Corner (Rating Upgrade)
2024: Pfizer: Undervalued Healthcare Leader Poised For Further Recovery_ seekingalpha.com
2024: Pfizer's 2025 'Boring' Outlook Had A Nice Surprise That Was Overlooked
2024: Pfizer's Innovative Drug Pipeline Provides Ample Reason To Buy It Here
2024: Pfizer's Innovative Drug Pipeline Provides Ample Reason To Buy It Here_seekingalpha
2024: Pfizer's Oncology Triumphs Keep Investors Hooked Amid Market Volatility
2024: Pfizer's Post-Pandemic Pivot
2024: Pfizer’s Oxbryta Withdrawal Leaves Sickle Cell Community Scrambling, Investors Reeling
2024: Results: Pfizer Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
2024: The Oncology Bet Is Already Paying Off For Pfizer
2024: Unveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth
2025: #2. Eliquis (apixaban) Bristol Myers Squibb and Pfizer 2024 Sales: $20.699 billion ($13.333 billion BMS + $7.366 billion Pfizer) 2023 Sales: $18.953 billion ($12.206 billion BMS + $6.747 billion Pfizer) % Change: +9.2%
2025: At $25 Is Pfizer Stock Deep Value Or A Falling Knife?
2025: Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates
2025: Pfizer hints at acquisitions to boost obesity pipeline after trial setback
2025: Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
2025: Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down
2025: Pfizer Remains A Good Pick For Dividend Investors
2025: Pfizer Remains A Good Pick For Dividend Investors
2025: Pfizer revenue 2024
2025: Pfizer Scraps Obesity Pill After Potential Drug-Tied Liver Injury
2025: Pfizer strikes deal with Trump: lower prices, new website, no tariffs
2025: Pfizer to offer cheaper US drugs via Trump's website in new deal
2025: Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors_ seekingalpha.com
2025: Pfizer: Bearish Catalysts Brewing
2025: Pfizer: Better To Face The Harsh Reality Than Continue Waiting
2025: Pfizer: Finally Some Fortune, Plus Twenty High-Quality Dividend Growth Valuations
2025: Pfizer: I Should Have Sold Earlier (Downgrade)
2025: Pfizer: Investors Won't Stick Around Forever
2025: Pfizer: It's Time To Play Defensive
2025: Pfizer: No More Growth - Still A Worthy Dividend Buy
2025: Pfizer: Pipeline Monetization Shows Great Promise - Rich Yields Pending Re-Rating
2025: Pfizer: Stagnation Is An Investment Opportunity
2025: Pfizer: Undervalued Safe Haven In Risk-Off Market_seekingalpha.com
2025: Pfizer's 2025 Comeback: What's Driving Growth
2025: Pfizer's Comeback Accelerates
2025: Pfizer's SWOT analysis: stock outlook amid pipeline progress and market challenges
2025: Pfizer's Turnaround Story Is Stronger Than You Think
2025: Terrible News for Pfizer Stock Investors
2025: Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline
2026: Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
2026: Pfizer Stock: The AI Hedge That Pays You To Stay Defensive (NYSE:PFE)
2026: Pfizer Stock: The Post-Pandemic Turnaround Is Already Underway (NYSE:PFE) | Seeking Alpha
2026: Pfizer: Firing On All Cylinders
Developments: Pfizer (Archives 2011-2014)
Developments: Pfizer (Archives 2015-2021)
Pfizer Ventures
Jumps
*Key People: Pfizer
Finance & Acquisition: Pfizer